Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer:doubts no more.

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill mosttumour cells because of recognition by T cell receptor and natural killerreceptors.OBJECTIVE: We discuss the possibility that the intentional activation ofgammadelta T cells in vivo by aminobisphosphonates may represent a promisingtarget for the design of novel and highly innovative immunotherapy in cancerpatients.METHODS: The antitumoral effects of gammadelta T cells both in vitro and invivo have been demonstrated suggesting a new therapeutic approach fortranslation into the clinical setting.RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent aparticularly interesting target for immunotherapeutic protocols based on N-aminobisphosphonate administration and several Phase I-II trials are ongoinginvestigating the activity of zoledronic acid plus IL-2 in solid tumours.
Original languageEnglish
Pages (from-to)875-883
Number of pages9
JournalExpert Opinion on Biological Therapy
Volume8(7)
Publication statusPublished - 2008

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer:doubts no more.'. Together they form a unique fingerprint.

  • Cite this